AngioDynamics Announces Inducement Grants for New CEO Eric Honroth
AngioDynamics, Inc. has granted inducement awards to Eric Honroth in connection with his appointment as Chief Executive Officer, effective November 2, 2026.
Stocks · News reference
AngioDynamics reported the publication of findings from its DIRECT study and the establishment of a new Category I CPT code for pancreatic irreversible electroporation (IRE).
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
AngioDynamics, Inc. has granted inducement awards to Eric Honroth in connection with his appointment as Chief Executive Officer, effective November 2, 2026.
AngioDynamics, Inc. announced that its management team is scheduled to participate in upcoming investor conferences, including a fireside chat at the UBS Global Healthcare Conference.
AngioDynamics (ANGO) reported Q1 FY2027 adjusted loss of 4 cents per share, beating estimates by 60%, with revenues up 6.9% to $80.9 million. Med Tech revenues grew 13.2%, driven by strong performance from Auryon, AlphaVac, and NanoKnife. Gross margin expanded 410 basis points to 59.4%, though the stock fell over 20% following the announcement. The company reiterated FY2027 guidance of $336-$341 million in revenues with Med Tech expected to grow 12-15%.
ANGO stock drops 21% as AngioDynamics reports Q1 results, names Eric Honroth as new CEO, and reaffirms FY27 guidance.